A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)

@article{Strner2017ASF,
  title={A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)},
  author={Klarissa Hanja St{\"u}rner and Jan-Patrick Stellmann and Jan D{\"o}rr and Friedemann Paul and Tim Friede and Sven Schammler and Stefanie Reinhardt and Susanne Gelli{\ss}en and Gainet Weissflog and Tobias Djamsched Faizy and Oliver Werz and Sabine Fleischer and Lea A. I. Vaas and Frank Herrmann and Ole Pless and Roland Martin and Christoph Heesen},
  journal={Journal of Neurology, Neurosurgery, and Psychiatry},
  year={2017},
  volume={89},
  pages={330 - 338}
}
Objective To investigate whether oral administration of a standardised frankincense extract (SFE) is safe and reduces disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Methods We performed an investigator-initiated, bicentric phase IIa, open-label, baseline-to-treatment pilot study with an oral SFE in patients with RRMS (NCT01450124). After a 4-month baseline observation phase, patients were treated for 8 months with an option to extend treatment for up to 36… Expand
Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
TLDR
Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period, however, treatment response to anSFE seems to be related to 12-,15-LO and cyclooxygenase product levels before SFE exposure. Expand
Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis
  • F. Patti
  • Medicine
  • Journal of Neurology, Neurosurgery, and Psychiatry
  • 2017
Over the last 20 years, the treatment landscape of relapsing-remitting multiple sclerosis (RRMS) has impressively changed and new oral first-line agents have been licensed. Indeed, from a completeExpand
Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis
TLDR
Overall CL-Vs decreased during the follow-up period and were associated with improvements of cognitive and disability status scores and the presence of short-term CL-V dynamics in RRMS patients is suggested. Expand
Boswellic acids/Boswelliaserrata extract as a potential COVID-19 therapeutic agent in the elderly
TLDR
A small to moderate dose B. serrata extract may be useful in the enhancing adaptive immune response in mild to moderate symptoms of COVID-19, however, large doses of BA may be beneficial in suppressing uncontrolled activation of the innate immune response. Expand
Protective Effect of Casperome®, an Orally Bioavailable Frankincense Extract, on Lipopolysaccharide- Induced Systemic Inflammation in Mice
TLDR
Evaluating if Casperome® (Casp), an orally bioavailable soy lecithin-based formulation of standardized frankincense extract, is able to ameliorate systemic effects and organ damages induced by severe systemic inflammation using a murine model of sepsis showed anti-inflammatory, anti-oxidative, and hepatoprotective effects. Expand
The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review
TLDR
Many nutrients and phytonutrients are capable of significantly modulating immune function and reducing inflammation, according to multiple biomarkers in clinical trials in different populations of adults with varying health statuses. Expand
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities.
TLDR
Clinical trials showed the efficacy of frankincense and its phytochemicals against osteoarthritis, multiple sclerosis, asthma, psoriasis and erythematous eczema, plaque-induced gingivitis and pain, and the therapeutic potential against other tumor types is still speculative. Expand
Approaches for the treatment of neurodegenerative diseases related to natural products
TLDR
This chapter aimed to summarize the most important compounds originated from natural sources that were targets of clinical studies, associated with neurological and psychiatric disorders, obtaining a total of 13 articles, in the last 10 years, and characterized these compounds structurally. Expand
Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
  • H. Ammon
  • Medicine
  • Phytomedicine : international journal of phytotherapy and phytopharmacology
  • 2019
TLDR
Preclinical and clinical data suggest that BE and/or 11-keto-ß-boswellic acids by inhibiting the expression of proinflammatory cytokines from immune-competent cells, may prevent insulitis and insulin resistance in type 1 and type 2 diabetes, respectively, and therefore may be an option in the treatment/prevention of type 1/2 diabetes. Expand
Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products
TLDR
Structures of 5-lipoxygenase (5-LOX) reveal that NDGA disturbs regions that shield the active site while AKBA binds an allosteric site that changes the enzyme’s regiospecificity. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis
TLDR
B. papyrifera showed significant improvement in visuospatial memory, but had no effect on verbal memory and information processing speed in multiple sclerosis patients. Expand
Evolving concepts in the treatment of relapsing multiple sclerosis
TLDR
Before starting a treatment, neurologists should carefully consider the state of the disease, its prognostic factors and comorbidities, the patient's response to previous treatments, and whether the patient is likely to accept treatment-related risks in order to maximise benefits and minimise risks. Expand
Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
TLDR
Baseline GD-enhancing lesions predict evolution of Gd- and T2 lesions after 6 months and might be used to control for regression to the mean effects. Expand
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
TLDR
Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as assessed by means of MRI, but was not associated with a significantly lower risk of disability progression confirmed at 12 weeks. Expand
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
TLDR
The association of fatigue and depression suggests that there might be either common underlying mechanisms or interdependence by a cause-and-effect relationship that requires further investigation. Expand
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
TLDR
It is excluded the possibility that CELs can be a good surrogate for relapses over the time scales investigated, as well as the ability to test a wide range of imaging- and clinically-based hypotheses for surrogacy. Expand
Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis
TLDR
Overall CL-Vs decreased during the follow-up period and were associated with improvements of cognitive and disability status scores and the presence of short-term CL-V dynamics in RRMS patients is suggested. Expand
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
TLDR
Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Expand
Frankincense: systematic review
  • E. Ernst
  • Medicine
  • BMJ : British Medical Journal
  • 2008
TLDR
The evidence for the effectiveness of B serrata extract as a treatment for any human medical condition is encouraging but not compelling. Expand
Update on disease-modifying therapies for multiple sclerosis
TLDR
It is imperative that prompt and adequate treatment be established on diagnosis and changes in therapy should be considered when there is evidence of disease activity as well as accumulation of disability or safety or tolerability concerns. Expand
...
1
2
3
4
...